Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 824 across all filing types
Latest filing 2023-05-24 Capital/Financing Update
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Capital/Financing Update Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The content explicitly states, 'Attached hereto is a report on *Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds*'. This indicates the document itself is an announcement about a financing event (a private placement) and directs the reader to an attached file. Since the core subject is a financing activity ('$60 Million Private Placement'), the most specific category is Capital/Financing Update (CAP). However, given the structure—a brief regulatory filing announcing an attached document—it could also be considered a general Regulatory Filing (RNS). Since the subject matter is clearly defined as a financing event, CAP is more precise than the general RNS fallback. The document length is short (1871 chars), but it is announcing a specific corporate action rather than just announcing the publication of a periodic report (which would favor RPA). Therefore, CAP is the best fit for a financing announcement.
2023-05-24 English
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Earnings Release Classification · 1% confidence The document is explicitly identified as a "FORM 6-K" filed with the SEC by a Foreign Private Issuer (Kamada Ltd.) for the month of May 2023. The core content of the filing (Exhibit 99.1) is an announcement stating that the company "will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023" and will host a conference call. This structure—a regulatory filing announcing the upcoming release of earnings and a conference call—is characteristic of an Earnings Release (ER) or a precursor to one. Since the document itself is the announcement of the results release and call, and not the full results (which would likely be an ER or CT), it functions as the initial notification. However, the filing type (6-K) is a general reporting mechanism for foreign issuers. The content specifically relates to the upcoming release of quarterly financial results and a conference call. This aligns best with the Earnings Release (ER) category, as it is the primary communication regarding the period's financial performance announcement, even if the actual detailed results are forthcoming. If the document were only the announcement of the *date* of the report publication without mentioning the results themselves, RPA might apply, but here the subject is explicitly the Q1 2023 Financial Results announcement and call. Given the context of quarterly results announcement, ER is the most appropriate classification for the *subject matter* being reported via the 6-K. Q1 2023
2023-05-17 English
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Report Publication Announcement Classification · 1% confidence The document is a very short filing (1910 characters) published on May 17, 2023, via the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE). The title explicitly states: "Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023". Crucially, the text ends with: "Attached hereto is a report on*Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023* *ea178805-6k_kamadaEDGAR1_Bannerless_isa.pdf*". This structure—a brief announcement stating that the actual report/details are attached or linked—fits the definition of a Report Publication Announcement (RPA) perfectly, rather than the full Earnings Release (ER) or Interim Report (IR) itself. It is an announcement *about* the upcoming release/call.
2023-05-17 English
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed as a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' for the month of May 2023. Form 6-K filings are used to report material information that a foreign private issuer makes public in its home country or furnishes to the SEC. The content attached as Exhibit 99.1 is an announcement regarding the receipt of marketing authorization for a drug in Switzerland. This type of material, non-periodic disclosure by a foreign private issuer is typically classified under the general regulatory filing category, as there is no specific code for a 6-K filing itself, nor does it fit perfectly into the other specific categories like ER, IR, or AR. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a standard SEC Form 6-K submission that is not a primary financial report (like 10-K or IR) or a specific announcement type (like DIV or DIRS). The document length is substantial (over 13k characters), so it is not an RPA.
2023-05-16 English
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Report Publication Announcement Classification · 1% confidence The document is a very short filing (1972 characters) from KAMADA LTD, reporting to the Israel Securities Authority and the Tel Aviv Stock Exchange. It is titled 'Immediate Report' and explicitly states, 'Attached hereto is a report on*Kamada Announces Receipt of Marketing Authorization for Glassia� for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland*'. This structure—a brief announcement referencing an attached or linked document—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is not the full report itself, but the announcement of its publication.
2023-05-16 English
U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed by a Foreign Private Issuer (Kamada Ltd.) with the SEC. Form 6-K is used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. This type of filing is generally considered a miscellaneous regulatory announcement that doesn't fit neatly into the standard US periodic reports (like 10-K or 10-Q). The content is an announcement regarding U.S. FDA approval for manufacturing a product, which is material information released to the public. Since Form 6-K is not one of the specific codes provided (like 10-K, ER, IR), and it serves as a general regulatory disclosure mechanism for foreign issuers, the most appropriate fallback category is Regulatory Filings (RNS). The document length (10,871 chars) is substantial, indicating it is the primary report/announcement itself, not just a brief notice of publication.
2023-05-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.